Patients and healthcare providers benefits

Patients Physicians Policymakers
Early-stage pancreatic cancer detection (stage I and II) increases 5-year survival rates A reliable diagnostic tool at a disease stage where no tools are currently available New possibility to introduce procedures for risk surveillance of high-risk groups
Non-invasive diagnostic procedure (blood test vs. CT scan/biopsy) Test result can motivate more expensive diagnostic procedures, based on the result of the blood test A concrete tool for implementing personalized medicine policies
Available for high-risk patients even before symtoms are discovered   Supports the implementation of the In Vitro Diagnostic Medical Devices Directive 98/79/EC (IVD Directive) and US Recalcitrant Act 2012

  Note: : IMMray™ PanCan-d is not available yet as several clinical evidence studies are ongoing